HIV PrEP and Treatment Not Reaching Black and Hispanic/Latino Gay and Bisexual Men
The first injectable PrEP option for HIV may help reduce inequities among Black and Hispanic/Latino gay and bisexual men.
HIV Pre-Exposure Prophylaxis
FDA Approves Apretude, a Long-Acting Injectable for HIV PrEP
The application is supported by data from the phase 2b/3 HPTN 083 and HPTN 084 trials, which evaluated the efficacy and safety of Apretude for HIV PrEP.
Effects of HIV Pre-Exposure Prophylaxis on High-Risk Sexual Behaviors in Men Who Have Sex With Men
Investigators conducted a study to assess the rates of high-risk sexual behavior and sexually transmitted infections among men who have sex with men before and after the introduction of HIV pre-exposure prophylaxis.
Outcomes of a Tailored HIV Pre-Exposure Prophylaxis Service for Individuals Who Inject Drugs
Researchers conducted a study that assessed the use of an HIV pre-exposure prophylaxis service tailored to individuals who inject drugs.
Does Increased Adherence to HIV PrEP With Emtricitabine/Tenofovir Decrease the Risk for Incident HIV Infection?
Researchers conducted a study to determine whether there is an association between increased adherence to HIV pre-exposure prophylaxis with daily emtricitabine/tenofovir disoproxil fumarate and a decreased risk for incident HIV infection.
Increased Persistence, Re-Initiation of HIV Pre-Exposure Prophylaxis Found Among Patients Treated With Emtricitabine/Tenofovir Alafenamide
Investigators conducted a study that compared the rate of persistence and re-initiation of HIV pre-exposure prophylaxis among patients treated with emtricitabine/tenofovir alafenamide vs those treated with emtricitabine/tenofovir disoproxil fumarate.
Association Between Tenofovir Disoproxil Fumarate and Weight Loss in Individuals who Test Negative for HIV Infection
Researchers conducted a study to determine whether tenofovir disoproxil increases the likelihood for weight loss for the treatment of patients who were negative for HIV infection.
Disproportionate Gaps in HIV Pre-Exposure Prophylaxis Care Continuum Found Among Certain Patient Populations
Researchers sought to characterize disproportionate gaps in the HIV pre-exposure prophylaxis care continuum, and to identify patients at increased risk for early discontinuation of PrEP.
Association Between Drug Feedback and HIV Pre-Exposure Prophylaxis Adherence Among Young Women in Southern Africa
Researchers sought to assess whether retrospective drug feedback increased adherence to HIV pre-exposure prophylaxis among young women in South Africa and Zimbabwe.
Some High-Priority Groups More Likely to Stop Taking PrEP
Younger individuals, African American and Latinx, those with substance use disorders more likely to discontinue PrEP.
- Loading...
Loading...
Loading... 
Loading...